PubMed Health⌕ Search

Biomedical subjects

A C Jenkins

Publications and source records attributed to A C Jenkins.

At least 19 recordsLinked to original sources
PubMed2000

Frictional properties of cattle hooves and their conformation after trimming.

The conformation of the hooves of nine heifers obtained from an abattoir was measured and their coefficient of static friction (mu) was determined for movement in forward, backward and sideways directions. The hooves were trimmed by the Dutch method and their conformation and p were measured again. Trimming increased mu, and decreased the length of the digit and the angle between it and the floor. The value of mu was considerably greater for movement in a forward or backwards direction than sideways. The relationship between the value of mu for sideways movement and hoof conformation was examined by using 52 lower limbs from a variety of cattle breeds. Although mu was greater for Belgian blue than other cattle breeds, there were no relationships between mu and hoof conformation, including a measure of the roughness of the sole.

Animal Husbandry↗
PubMed1995

Characterization and localization of the equine herpesvirus 1 major DNA binding protein.

In previous studies of equine herpesvirus 1 (EHV-1) gene regulation, we observed an abundant early infected cell polypeptide (ICP), designated ICP130, which appeared in reduced amounts in cells infected with defective interfering particle-rich EHV-1 stocks compared to standard EHV-1-infected cells. To characterize this ICP further, a monoclonal antibody (MAb) was developed to EHV-1 ICP130 and used to (1) affinity purify ICP130, (2) examine ICP130's ability to bind DNA, and (3) define the synthesis and intracellular localization of ICP130 during productive EHV-1 infections. Although anti-ICP130 MAbs did not crossreact with any HSV-1 protein in immunoblots, a polyclonal antiserum against HSV-2 major DNA binding protein (ICSP11,12) did react with purified EHV-1 ICP130. DNA band shift assays indicated that (1) the mobility of shifted bands representing DNA/EHV-1-infected cell protein complexes was further decreased by the addition of either anti-ICP130 MAbs or anti-ICSP11,12, but not by the addition of irrelevant MAbs, (2) the ability of ICP130 to complex with DNA was not sequence dependent, (3) ICP130 associated with both single- and double-stranded oligomers, and (4) similar supershifted patterns were produced using affinity-purified ICP130 and anti-ICP130 MAbs. During productive infection, ICP130 initially localized rapidly and exclusively to the infected cell's nucleus in a generalized, fine granular pattern. Over the course of infection, this pattern typically progressed to include several large, intensely reactive intranuclear granules, and by 6 hr p.i. some cytoplasmic reactivity also was visible. In < 5% of the cells, a dense, fibrillar network surrounding the nucleus was observed instead. The progressive changes in nuclear localization depended upon the onset of viral DNA replication, and once the late pattern was established, ongoing DNA synthesis was required to maintain it. The results indicate that ICP130 is the previously reported EHV-1 counterpart of the HSV major DNA-binding protein and is similar, but not identical, in many aspects.

Animals↗
PubMed1992

A mosquito neuropeptide in a moth larva (Helicoverpa zea): relation to FMRF-amide immunoreactivity.

The cerebral nervous and midgut endocrine systems of the larval corn earworm, Helicoverpa zea, were examined using light microscopy and immunocytochemistry for RF-amide family peptides. Immunoreactivity for a mosquito neuropeptide, Aedes Head Peptide-I (Aea-HP-I,pERPhPSLKTRFa), is widely distributed in this lepidopteran. Immunostaining for Aea-HP-I is localized (1a) in perikarya and axons of the brain, the subesophageal ganglion, and the first thoracic ganglion, (b) in peripheral axons innervating muscles of the midgut, and (2) in numerous midgut endocrine cells. Aea-HP-I-associated activity generally occurs as a subset of FMRF-amide (FMRFa; a molluscan cardioactive peptide) immunoreactivity. Cross-reactivity studies indicate that Aea-HP-I and FMRFa immunoreactivities are heterogeneous in the cerebral nervous system and in axons innervating the muscles of the midgut, but may be homogeneous in midgut endocrine cells. Radioimmunoassay for Aea-HP-I reveals immunoreactivity in hemolymph, as well as in extracts of midguts and heads.

Amino Acid Sequence↗
PubMed1985

Captopril in hypertension; seven years later.

Captopril was first administered to hypertensive patients 7 years ago. The relatively high dosage employed and the severity of diseases in the patient population initially led to a high frequency of side effects. Subsequently, an increase in the time intervals for dose titration and the earlier addition of a diuretic have made it possible to reduce the daily dose, thus significantly improving the drug's safety profile without compromising its antihypertensive effect. In a worldwide postmarketing surveillance study of captopril, 6,737 hypertensive patients were enrolled, of whom 3,219 were treated for at least 1 year. Patients had a mean entry blood pressure of 183 (+/- 31)/111 (+/- 16) mm Hg while still receiving an average of 2.3 antihypertensive drugs. However, 10.3% were not receiving therapy before entering the study. 1,811 patients (29% of those for whom relevant data were available) had impaired renal function on entry (serum creatinine concentration greater than or equal to 1.6 mg/dl). The hypertension of 881 of the patients (13.1%) was classified as mild to moderate. By design, the types of patients, dosage schedules, and patient monitoring requirements were consistent with the recommendations of the manufacturer at the time the study was initiated. The results of the study showed that long-term antihypertensive efficacy was maintained with a mean captopril dose of approximately 150 mg/day, when used either as monotherapy or more frequently with a diuretic. This dosage was associated with satisfactory control of blood pressure and a considerable reduction in the 12 months' cumulative frequency of drug discontinuation because of adverse reactions (5.8%).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1985

Captopril in the treatment of the elderly hypertensive patient.

As part of a large multicenter surveillance study of captopril, 975 hypertensive patients aged 65 years or older were treated, 418 of whom received the drug for at least 12 months. Blood pressure was lowered from an entry level of 193/105 +/- 30/16 (mean +/- SD) to 159/88 +/- 25/12 mm Hg, and side effects were infrequent. During treatment, renal function was undisturbed in the majority of patients. The frequency of clinically evident hypotensive episodes did not differ from that found in the total study population, suggesting that in this age group, despite the reduction in blood pressure, cerebral perfusion was maintained. This experience suggests that captopril can be used for the treatment of the elderly hypertensive patient.

Aged↗